AF-DKP (Selank Metabolite)
AF-DKP is an active cyclic dipeptide (diketopiperazine) metabolite of Selank with independent GABAergic and anxiolytic pharmacological activity, formed during enzymatic degradation of the parent heptapeptide.
AF-DKP (cyclo-Pro-Gly diketopiperazine) is an active metabolite generated during the enzymatic degradation of Selank, the synthetic heptapeptide anxiolytic developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Unlike most peptide metabolites that are pharmacologically inert degradation products, AF-DKP possesses independent anxiolytic and GABAergic activity that contributes to and may extend the therapeutic effects of Selank beyond the parent compound's short half-life.
Overview
Diketopiperazines (DKPs) are the smallest possible cyclic peptides, formed by intramolecular cyclization of dipeptide sequences. They are common metabolic products of linear peptides and proteins, and several DKPs have been found to possess significant biological activity independent of their parent molecules. The Pro-Gly DKP derived from Selank's C-terminal Pro-Gly-Pro extension represents a pharmacologically active end product of Selank metabolism.
This finding is significant because Selank has a very short plasma half-life (minutes), yet its anxiolytic effects persist for hours after administration. The generation of AF-DKP as a stable, bioactive metabolite provides a partial explanation for this pharmacokinetic-pharmacodynamic disconnect — the parent peptide is rapidly degraded, but its metabolic products continue to exert GABAergic effects.
Mechanism of Action
AF-DKP exerts anxiolytic effects primarily through modulation of the GABAergic system. The cyclic dipeptide enhances inhibitory GABAergic neurotransmission by allosteric modulation of GABA-A receptors, increasing the frequency and/or duration of chloride channel opening in response to GABA binding. This mechanism is functionally similar to but pharmacologically distinct from benzodiazepine modulation of the same receptor complex.
The diketopiperazine ring structure confers metabolic stability far exceeding that of the linear Pro-Gly dipeptide, as cyclic peptides resist degradation by exopeptidases. This stability allows AF-DKP to accumulate and maintain GABAergic activity long after the parent Selank molecule has been fully degraded.
The metabolite also appears to contribute to Selank's overall immunomodulatory profile, though its immune effects are less well-characterized than its anxiolytic activity. DKPs as a class have been shown to interact with various biological targets including opioid receptors, serotonin receptors, and inflammatory mediators.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Independent Anxiolytic Activity
Studies at the Institute of Molecular Genetics demonstrated that AF-DKP produces anxiolytic effects in standard behavioral assays (elevated plus maze, light-dark box) when administered independently of the parent compound Selank. These effects are comparable in direction though not in magnitude to Selank itself, consistent with AF-DKP representing one of several active components contributing to the overall pharmacological profile of Selank administration.
GABAergic Mechanism
Electrophysiological studies have shown that DKP metabolites of neuropeptides can modulate GABA-A receptor function. The Pro-Gly DKP enhances GABAergic inhibitory tone, which aligns with the anxiolytic behavioral effects observed in vivo. This GABAergic activity is independent of benzodiazepine binding sites and does not produce the sedation, tolerance, or dependence associated with classical benzodiazepine anxiolytics.
Selank Metabolism and Active Metabolites
The metabolic pathway of Selank involves sequential degradation by serum peptidases. The C-terminal Pro-Gly-Pro extension — originally added to the tuftsin core to improve metabolic stability — generates the Pro-Gly DKP as a terminal metabolic product through intramolecular cyclization. This represents an elegant example of "active metabolite" pharmacology, where drug metabolism generates new bioactive species rather than merely inactivating the parent compound.
Diketopiperazine Pharmacology
DKPs are an increasingly recognized class of bioactive molecules. Naturally occurring DKPs from microbial sources exhibit antibacterial, antifungal, antiviral, and antitumor activities. Endogenous DKPs formed from neuropeptide metabolism may represent an underappreciated signaling pathway in the central nervous system, with implications for understanding how short-lived peptide neurotransmitters produce long-lasting biological effects.
Implications for Peptide Drug Design
The discovery that Selank generates a pharmacologically active DKP metabolite has broader implications for peptide drug design. It suggests that the therapeutic profile of a peptide drug may reflect not only the parent compound's activity but also the cumulative contributions of its metabolic products. This "pro-drug cascade" model — where a single administered peptide generates multiple active species with distinct pharmacological profiles and kinetics — may apply to other therapeutic peptides with C-terminal Pro-Gly or similar DKP-forming sequences.
Safety Profile
Diketopiperazines are among the most common cyclic peptide structures in nature, found in fermented foods, roasted coffee, cocoa, beer, and bread. Humans consume milligram quantities of various DKPs daily through normal dietary intake.
AF-DKP as an endogenous metabolite of an approved pharmaceutical (Selank is approved in Russia) is expected to have a favorable safety profile. Diketopiperazines are naturally occurring compounds found in food, beverages, and as normal products of human protein metabolism. The Pro-Gly DKP is formed in vivo during normal Selank administration and is thus implicitly included in Selank's clinical safety data. The metabolic stability of cyclic dipeptides means AF-DKP is eventually eliminated through renal clearance rather than further enzymatic degradation. No independent toxicity data for isolated AF-DKP have been published, but no adverse effects attributable to this metabolite have been reported in Selank safety studies.
Pharmacokinetic Profile
AF-DKP (Selank Metabolite) — Pharmacokinetic Curve
Interactions
Peptide Interactions
AF-DKP is an endogenous metabolite generated from Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) and tufsin degradation. It retains independent anxiolytic and immunomodulatory activity. When Selank is administered, AF-DKP is produced in vivo, so co-administration would be redundant but not harmful. (Zozulya et al., 2001, Immunopharmacology)
AF-DKP modulates GABA-A receptor allosteric sites, enhancing GABAergic tone. Combining it with benzodiazepines or other GABAergic compounds may produce additive anxiolytic effects but also additive sedation. Preclinical data from diketopiperazine studies suggest potentiation of GABA-mediated inhibition. (Uchida et al., 2011, Bioorg Med Chem)
Quality Indicators
What to look for
- Well-established safety profile
- Naturally occurring compound
Caution
- Short half-life may require frequent dosing
Frequently Asked Questions
References (4)
- [1]Zolotarev YA et al Metabolism of Selank and its fragments in the blood of rats and their distribution in the organs Bioorg Khim (2016)
- [3]
- [2]Kozlovskii II, Danchev ND Optimizing dosage regimen of Selank using the method of active avoidance Bull Exp Biol Med (2003)
- [4]Kozlovskaya MM et al The anxiolytic-like activity of Selank Bull Exp Biol Med (2003)
AEDP (Kidney Bioregulator)
AEDP (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide bioregulator investigated for tissue-specific effects in renal aging, nephroprotection, and kidney gene expression modulation within the Khavinson bioregulatory peptide framework.
AF2121
AF2121 is an extended ADNP-derived peptide fragment longer than NAP (NAPVSIPQ), developed in the Gozes laboratory at Tel Aviv University, with preclinical evidence for tau interaction, microtubule stabilization, and cognitive enhancement in neurodegenerative disease models.